Drug intelligence / Profile preview

Epicelline

Development stage: Unknown
Lead developer: Beiersdorf
Modality: Small Molecules
Administration: Topical

Overview

Epicelline is a proprietary cosmetic active ingredient developed by Beiersdorf that functions as an epigenetic modulator to address skin aging. Discovered through Beiersdorf's patented skin-specific age clock technology, the ingredient targets age-dependent epigenetic changes by reversing DNA methylation. This mechanism reactivates 'youth genes' that have been silenced by biological aging and environmental factors such as UV exposure and stress. Epicelline was commercialized in 2024 within the Eucerin Hyaluron-Filler Epigenetic Serum and expanded to the NIVEA Cellular Epigenetics Rejuvenating Serum in 2025, marking a significant application of epigenetic research in topical skincare.

Brand names: Epicelline
Other names: Epicelline

Targets

DNA

Beyond the preview

Go deeper on Epicelline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epicelline.

Explore the full profile